Archives

Law: Seniors Self-Diagnosing and Treating: A Brave (and scary) New World-RECORDED WEBINAR

About this Course

This course is a recorded (home study version) of the 2024 CE Finale Encore Webinars.

 

Learning Objectives

Upon completion of this application based CE Activity, a pharmacist will be able to:

Describe the reasons seniors are increasingly diagnosing and treating themselves with therapies
Describe the legal and regulatory pathways that provide seniors access to therapies outside the drug supply chain
Describe the ways that pharmacists can recommend dietary supplements that are free of adulterants and contaminants
Describe the risks associated with self-treatment with dietary supplements, “peptides”, and counterfeit drug

Release and Expiration Dates

Released:  December 13, 2024
Expires:  December 13, 2027

Course Fee

$17 Pharmacist

ACPE UAN

0009-0000-24-044-H03-P

Session Code

24RW44-BVF28

Accreditation Hours

1.0 hours of CE

Additional Information

 

How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.  Don't forget to use the session code above, or that was sent to you in your confirmation email NOT the one on the presentation!

Accreditation Statement

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-24-044-H03-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Grant Funding

There is no grant funding for this activity.

Faculty

C. Michael White, PharmD, FCCP, FCP
BOT Distinguished Professor and Chair of Pharmacy Practice
University of Connecticut School of Pharmacy
Storrs, CT

Faculty Disclosure

In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

  • Dr. White has no financial relationships with ineligible companies.

Disclaimer

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Content

Handouts

Post Test

    Pharmacist Post Test

     

    1. Don is a 72-year-old who is looking online for alternatives to self-manage his pain. His prescriber told him he would not write any other prescriptions for oxycodone with APAP. He is looking at kratom and for Canadian Pharmacies that don’t require a prescription. Which of the following is the motivator for Don to transcend the normal medication supply chain?
    1. Cost of prescription options
    2. Circumvent prescriber gatekeeping restrictions
    3. Embarrassment over his health issue

     

    1. You are a pharmacist at a community pharmacy and a patient asks you which supplements to buy. What is a validated way to assure the dietary supplement you recommend does not have excessive microbial or heavy metal contamination and has the ingredients in the tablets/capsules advertised on the label?
    1. USP certification
    2. Better Homes and Gardens Certification
    3. The most expensive one

     

    1. Sylvia is a 68-year-old woman who weighs 120 pounds but wants to weigh 108 pounds like she did when she was 40 years old. Which of the following is a good counseling point if she reveals she is using a “peptide” GLP-1 product?
    1. Her obesity is a disorder that requires a GLP-1 product, so the benefits outweigh the risks
    2. These products are known to contain lead and arsenic in too high a level
    3. The labeled dose could vary, and she could overdose or underdose as a result

     

    1. Don from question 1 finds a “pharmacy” willing to sell him oxycodone with APAP for $7 a pill without a prescription. The site says it is a best seller in Canada. What is the main risk of Don getting his opioids from the unlicensed online site?
    1. Fentanyl adulteration and dose variability could lead to respiratory depression
    2. It is more expensive than the brand name prescription version he now takes
    3. The company offers no certificate of analysis or money back guarantee

     

    1. A company says its melatonin supplement can “support a restful sleep” and that “this product is not intended to diagnose, evaluate, or treat any disease.” What would the FDA call this?
    1. A legitimate health claim
    2. A legitimate quasi health claim
    3. A legitimate semi-health claim

     

    1. A woman calls a company that sells “Energy Macha” to complain that her newborn has an extra arm with seven fingers. How long does the company have to alert the FDA about this serious potential adverse event?
    1. 1-day
    2. 5-days
    3. 15-days

     

    1. Which of the following common adulterants is matched with the type of dietary supplement it is associated with?
    1. Weight Loss – human growth hormone
    2. Muscle Building – sildenafil
    3. Sexual Enhancement – tadalafil

     

    1. What is the name of the law that controls FDA authority over dietary supplements?
    1. DSHEA 1994
    2. OBRA 1990
    3. FDCA 1927

     

    VIDEO

    Patient Safety: Cheers to the Beers: Unpacking the Latest Updates for Safer Prescribing -RECORDED WEBINAR

    About this Course

    This course is a recorded (home study version) of the 2024 CE Finale Encore Webinars.

     

    Learning Objectives

    Upon completion of this application based CE Activity, a pharmacist will be able to:

    Review the role of the Beers Criteria in reducing potentially inappropriate medication (PIM) use and enhancing patient safety in older adults
    Identify recent updates to the Beers Criteria and their implications for medication management in geriatric care
    Apply the updated Beers Criteria to real-world scenarios, optimizing medication selection and minimizing risks in older adults

    Release and Expiration Dates

    Released:  December 13, 2024
    Expires:  December 13, 2027

    Course Fee

    $17 Pharmacist

    ACPE UAN

    0009-0000-24-045-H05-P

    Session Code

    24RW45-XTY89

    Accreditation Hours

    1.0 hours of CE

    Additional Information

     

    How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.  Don't forget to use the session code above, or that was sent to you in your confirmation email NOT the one on the presentation!

    Accreditation Statement

    The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-24-045-H05-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

    Grant Funding

    There is no grant funding for this activity.

    Faculty

    Kelsey Giara, PharmD
    Freelance Medical Writer
    Adjunct Faculty
    University of Connecticut School of Pharmacy
    Pelham, NH

    Faculty Disclosure

    In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

    • Dr. Giara has no financial relationships with ineligible companies.

    Disclaimer

    The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

    Content

    Handouts

    Post Test

    Learning Objectives
    • Review the role of the Beers Criteria in reducing potentially inappropriate medication (PIM) use and enhancing patient safety in older adults
    • Identify recent updates to the Beers Criteria and their implications for medication management in geriatric care
    • Apply the updated Beers Criteria to real-world scenarios, optimizing medication selection and minimizing risks in older adults

    1. About how many older adults are prescribed potentially inappropriate medications?
    A. One in seven
    B. One in five
    C. One in three

    2. Which of the following describes how age-related physiologic changes affect older adults?
    A. Decreased renal and hepatic blood flow slows drug excretion, causing toxicity
    B. Frailty increases activity in drug metabolizing pathways, making drugs less effective
    C. Decreased body fat and dehydration affect drug distribution and cause toxicity

    3. Which of the following best describes a potentially inappropriate medication?
    A. A drug that is contraindicated in patients older than 65 years
    B. A drug for which risks outweigh benefits in older adults
    C. A drug that should only be used in hospice or end-of-life care

    4. Which of the following is TRUE?
    A. Older adults should always avoid SGLT2 inhibitors
    B. The updated criteria removes doxepin < 6 mg/day C. Dabigatran is the safest anticoagulant for older adults 5. Which of the following best describes Beers Criteria guidance on proton pump inhibitors (PPIs)? A. Deprescribe after 8 weeks of scheduled use, unless the patient is high-risk B. After 8 weeks of scheduled use, reevaluate risks and benefits and continue if tolerated C. Avoid scheduled use completely and advise patients to use intermittent antacids 6. Which of the following is a reason to deprescribe a medication found on the Beers Criteria? A. The drug is being used to treat cancer but carries a risk of acid reflux B. The drug is being used to treat two indications at once C. The drug was prescribed to address the adverse effect of another drug 7. Mrs. Taylor, a 78-year-old woman with a history of AFib and diabetes, is prescribed rivaroxaban for stroke prevention and glyburide for glycemic control. During a consultation, she reports episodes of dizziness and has a recent lab result showing a creatinine clearance of 35 mL/min. Which of the following is the BEST plan of action? A. Recommend switching glyburide to glipizide B. Advise switching rivaroxaban to warfarin C. Continue both medications with increased monitoring for AEs

    VIDEO

    Immunization: Our Best Shot – Tips and Tools to Vaccinate Older Adults – RECORDED WEBINAR

    About this Course

    This course is a recorded (home study version) of the 2024 CE Finale Encore Webinars.

     

    Learning Objectives

    Upon completion of this application based CE Activity, a pharmacist will be able to:

    1.     RECOGNIZE appropriate vaccine recommendations for the older adult population
    2.      IDENTIFY potential barriers to vaccinations
    3.     ANALYZE current methods used to improve vaccination rates
    4.     DISCUSS ways to improve vaccine compliance in your patient population

    Release and Expiration Dates

    Released:  December 13, 2024
    Expires:  December 13, 2027

    Course Fee

    $17 Pharmacist

    ACPE UAN

    0009-0000-24-047-H06-P

    Session Code

    24RW47-FXY23

    Accreditation Hours

    1.0 hours of CE

    Additional Information

     

    How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.  Don't forget to use the session code above, or that was sent to you in your confirmation email NOT the one on the presentation!

    Accreditation Statement

    The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-24-047-H06-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

    Grant Funding

    There is no grant funding for this activity.

    Faculty

    Jack Vinciguerra, PharmD
    Express Scripts
    St Louis, MO

    Faculty Disclosure

    In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

    • Dr. Vinciguerra has no financial relationships with ineligible companies.

    Disclaimer

    The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

    Content

    Handouts

    Post Test

    Immunization: Our Best Shot - Tips and Tools to Vaccinate Older Adults

    After completing this continuing education activity, pharmacists will be able to

    • Recognize appropriate vaccine recommendations for the older adult population
    • Identify potential barriers to vaccinations
    • Analyze current methods used to improve vaccination rates
    • Discuss ways to improve vaccine compliance in your patient population

    1. How many vaccines does the CDC strongly recommend for older adults?
    a. Just two: influenza and COVID
    b. Three: influenza, COVID, and RSV
    c. Six-ish!!! (It depends)

    2. New patient, ES, age 60, has recently moved to Connecticut from Ontario, Canada. The patient reports receiving Zostavax 1 month ago. Which of the following recommendations regarding the administration of Shingrix is correct?
    a. Shingrix is contraindicated in those who have received Zostavax.
    b. It is recommended to administer the Shingrix vaccine immediately.
    c. It is recommended to wait at least 8 weeks after receiving Zostavax.

    3. Which of the following situations might act as a barrier to vaccine uptake in older adults?
    a. The nearest pharmacy and healthcare facilities are miles away and not on a bus route.
    b. Other people at the senior center have had COVID, the flu, or shingles recently and been quite ill.
    c. Pharmacy staff asks pleasantly and often if they might be ready to be vaccinated.

    4. Which of the following is an example of a contextual influence as defined by the Vaccine Hesitancy Determinants Matrix?
    a. Personal experience with vaccinations
    b. Communication and media environment
    c. Mode of vaccine administration

    5. Which of these programs is a federal program that uses digital outreach, television, print, and radio to decrease vaccine hesitancy among older adults?
    a. Risk Less, Do More
    b. It’s a Sure Shot
    c. No Shot in the Dark

    6. You’re monitoring vaccine uptake in your community and it is alarmingly low. You decide to use the S-H-A-R-E method of encouraging vaccine uptake. What does the R stand for?
    a. Remind patients that getting a vaccine-preventable disease is costly
    b. Remind patients that vaccines protect them and their loved ones
    c. Remind patients that you have the vaccines they need in stock

    Share the tailored reasons why the recommended vaccine is right for the patient
    Highlight positive experiences with vaccines (anecdotal or in practice) to strengthen confidence
    Address patient questions and concerns about the vaccine
    Remind patients that vaccines protect them and their loved ones
    Explain the potential costs of getting the disease

    VIDEO

    Beyond Memory Loss: Mastering the Management of Behavioral Symptoms in Dementia-RECORDED WEBINAR

    About this Course

    This course is a recorded (home study version) of the 2024 CE Finale Encore Webinars.

     

    Learning Objectives

    Upon completion of this application based CE Activity, a pharmacist will be able to:

    1.      Identify clinical characteristics of the behavioral symptoms of dementia (BSD) including agitation, psychosis, and sleep disturbances
    2.      Discuss medications currently used in the management of BSD along with emerging pharmacologic therapy options
    3.      Determine the most appropriate pharmacologic treatment option for a patient with behavioral symptoms of dementia based on patient-specific factors

    Release and Expiration Dates

    Released:  December 13, 2024
    Expires:  December 13, 2027

    Course Fee

    $17 Pharmacist

    ACPE UAN

    0009-0000-24-048-H01-P

    Session Code

    24RW48-YXF98

    Accreditation Hours

    1.0 hours of CE

    Additional Information

     

    How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.  Don't forget to use the session code above, or that was sent to you in your confirmation email NOT the one on the presentation!

    Accreditation Statement

    The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-24-048-H01-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

    Grant Funding

    There is no grant funding for this activity.

    Faculty

    Kristin Waters, PharmD, BCPS, BCPP
    Assistant Clinical Professor
    UConn School of Pharmacy
    Storrs, CT

    Faculty Disclosure

    In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

    • Dr. Waters is on the Johnson and Johnson speakers' bureau, but the information discussed here has no overlap. All financial relationships with ineligible companies have been mitigated.

    Disclaimer

    The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

    Content

    Handouts

    Post Test

      Behavioral Symptoms of Dementia Assessment Questions

      1. Which of the following is a symptom of agitation in dementia?
      1. Hallucinations
      2. Restless leg syndrome
      3. Throwing objects

       

      1. A 64-year-old patient has a PMH of AD, hypertension, urinary incontinence, and insomnia. Recently, they have been increasingly agitated throughout both the day and night. Symptoms primarily include pacing and verbally repeating the same phrases many times. Non-pharmacologic intervention is mildly effective, but the patient’s caregiver is requesting pharmacologic intervention as well.

      Current medications:

      Amlodipine 10 mg po daily

      Oxybutynin 10 mg po daily

      Diphenhydramine 25 mg po nightly prn insomnia

      Cetirizine 10 mg po daily

      Melatonin 6 mg po nightly Which of the following is the best first step in managing the patient’s agitation?

      1. Discontinue melatonin
      2. Reduce anticholinergic load
      3. Reduce dose of amlodipine

       

      3. The patient and caregiver agree to discontinuation of the cetirizine and diphenhydramine. They feel strongly that the oxybutynin improves their quality of life by allowing them to not become incontinent of urine overnight. Unfortunately, several weeks later the agitation symptoms persist. Which of the following is the best recommendations at this time?

      a. Initiate citalopram

      b. Initiate haloperidol

      c. Initiate risperidone

      1. A 71-year-old patient with vascular dementia recently started insisting that unknown people were living in his attic. He says he can hear the intruders talking during the night but they hide whenever someone goes up to check. The patient is extremely distressed about this and is trying to obtain a firearm to protect his family from these intruders.

      Which of the following pharmacologic recommendations may be appropriate?

      1. Brexpiprazole
      2. Trazodone
      3. Haloperidol

       

      1. The patient’s symptoms improve significantly after starting brexpiprazole. However, he is still very restless at night and wakes up frequently. He reports being “exhausted” each day. Which of the following would be the best pharmacologic option?
      1. Melatonin
      2. Eszopiclone
      3. Suvorexant

       

      6. Which medication approved for Parkinson’s disease psychosis has demonstrated the ability to prolong time to relapse of psychosis in Alzheimer’s disease?

      a. Brexpiprazole

      b. Pimavanserin

      c. Dexmedetomidine

       

      7. Which of the following behavioral symptoms of dementia is the most common?

      a. Apathy

      b. Psychosis

      c. Anxiety

      VIDEO

      Opioids: Impact of Palliative Care on Total Pain in the Older Adult-RECORDED WEBINAR

      About this Course

      This course is a recorded (home study version) of the 2024 CE Finale Encore Webinars.

       

      Learning Objectives

      Upon completion of this application based CE Activity, a pharmacist will be able to:

      Describe Palliative Care and its importance in the healthcare system today
      Define the concept of “total pain” and the importance of whole person care in pain and symptom management
      Recognize the physiologic changes that occur with aging and how those impact pain and symptom management
      Determine the role of the pharmacist in total pain management in the older adult

      Release and Expiration Dates

      Released:  December 13, 2024
      Expires:  December 13, 2027

      Course Fee

      $17 Pharmacist

      ACPE UAN

      0009-0000-24-046-H08-P

      Session Code

      24RW46-TXV63

      Accreditation Hours

      1.0 hours of CE

      Additional Information

       

      How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.  Don't forget to use the session code above, or that was sent to you in your confirmation email NOT the one on the presentation!

      Accreditation Statement

      The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

      Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-24-046-H08-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

      Grant Funding

      There is no grant funding for this activity.

      Faculty

      Megan Mitchell, PharmD, MS
      Pharmacy Clinical Coordinator Pain Management and Palliative Care
      University of Connecticut Healthcare
      Farmington, CT

      Faculty Disclosure

      In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

      • Dr. Mitchell has no financial relationships with ineligible companies.

      Disclaimer

      The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

      Content

      Handouts

      Post Test

      Opioids: Impact of Palliative Care on Total Pain in the Older Adult

      Post Test Questions

       

      1. Which of the following are goals of palliative care?
        1. Convince patients to enroll with hospice for end-of-life care
        2. Stop curative intent therapies to focus on comfort
        3. Improve quality of life for patients and families

       

      1. Which of the following is true regarding the differences between primary palliative care and specialty palliative care?
        1. Any individual healthcare provider can provide primary palliative care
        2. Primary palliative care always comes first
        3. Specialty palliative care always requires insurance prior authorization

       

      1. Which of the following is the IASP definition of pain?
        1. An unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage
        2. An unpleasant physical experience associated with, or resembling that associated with, actual or potential tissue damage
        3. An unpleasant emotional experience associated with, or resembling that associated with, actual tissue damage

       

      1. Approximately how much money is spent annually via direct medical costs, lost productivity and disability related to chronic pain in the United States?
        1. $5.6 billion
        2. $56 billion
        3. $560 billion

       

      1. Which of the following pain types is defined as maladaptive changes in pain processing and modulation without evidence of tissue or nerve damage?
        1. Nociceptive pain
        2. Nociplastic pain
        3. Neuropathic pain

       

      1. Which of the following is the correct definition of “total pain”?
        1. The total suffering of one’s physical, social, psychological and spiritual self that is experienced when dealing with serious illness
        2. The total suffering of one’s physical, social, psychological and spiritual self that is experienced with first time home buying
        3. The total suffering of one’s physical, social, psychological and spiritual self that is experienced when taking CE post-tests

       

      1. How does non-physical pain and suffering often manifest?
        1. Reports of worsening mood
        2. Reports of physical pain
        3. Reports of fear of dying

      VIDEO

      LAW: Call 1-800-Get-Cash Fast: Drug-Related Advertisements about Litigation RECORDED WEBINAR

      About this Course

      This course is a recorded (home study version) of the 2024 CE Finale Encore Webinars.

       

      Learning Objectives

      Upon completion of this application based CE Activity, a pharmacist will be able to:

      1.      Explain common terminology associated with commercials targeting older Americans
      2.      Describe legal processes associated with lawsuits generated against companies that make products alleged to cause harm
      3.      Discuss generalities in potential lawsuits associated with media promotion campaigns
      4.      Identify areas where no information is available to provide good, valid answers for patients who ask questions

      Release and Expiration Dates

      Released:  December 13, 2024
      Expires:  December 13, 2027

      Course Fee

      $17 Pharmacist

      ACPE UAN

      0009-0000-24-049-H03-P

      Session Code

      24RW49-ABC84

      Accreditation Hours

      1.0 hours of CE

      Additional Information

       

      How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.  Don't forget to use the session code above, or that was sent to you in your confirmation email NOT the one on the presentation!

      Accreditation Statement

      The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

      Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-24-049-H03-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

      Grant Funding

      There is no grant funding for this activity.

      Faculty

      Jeannette Y. Wick, RPh, MBA
      Director Office of Professional Pharmacy Development
      UConn School of Pharmacy
      Storrs, CT

      Faculty Disclosure

      In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

      • Ms. Wick has no financial relationships with ineligible companies.

      Disclaimer

      The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

      Content

      Handouts

      Post Test

        LAW: Call  1-800-Get-Cash Fast

         

        After completing this continuing education activity, learners will be able to

        • Explain common terminology associated with commercials targeting older Americans
        • Describe legal processes associated with lawsuits generated against companies that make products alleged to cause harm
        • Discuss generalities in potential lawsuits associated with media promotion campaigns
        • Identify areas where no information is available to provide good, valid answers for patients who ask questions

         

         

        1. What is the legal lingo for cases that are solicited on television using 1-800 numbers?
        1. Class action suits
        2. Torte claims
        3. Product liability suits

         

        1. What groups have traditionally been represented in parens patriae suits?
        2. State residents who appeal to the state to represent them
        3. Smokers and people who have opioid or alcohol use disorder
        4. Children, the mentally ill, people who are legally incompetent

         

        1. What is usury law?
        1. Laws pertaining to the use of a commercial product that results in alleged harm to a group of people who become plaintiffs
        2. Laws pertaining to  lending money at an interest rate that is unreasonably high or higher than the rate permitted by law
        3. Laws pertaining to any claim that arises in civil court, with the exception of contractual disputes, property, or criminal activity

         

        1. When discussing multi-district litigation (MDL), what does the adjective “generic” mean?
        1. It means that most torte claims do not include generic drugs; they focus on brand names
        2. It means assets (documents, expert opinion, interviews, etc) that apply to all plaintiffs
        3. It means developing charts, timelines, and visuals that a judge and jury will understand

         

        1. A patient asks you if you can determine how much money he might get if he joins a multi-district litigation on ranitidine. What do you say?
        1. Call the 1-800 number advertised on TV; the operator can provide that information.
        2. Go to the local library and access LegalTrac; settlement amounts are tracked closely.
        3. That information is guarded closely by nondisclosure agreements; it’s hard to tell.

         

        1. What is the Texas Two-Step in the legal arena?
        2. A term describing division of assets and liabilities between two companies
        3. A term describing a non-opt-out settlement for mass tort liability
        4. A term describing companies’ tendency to declare bankruptcy swiftly

         

        1. In a case against a major pharmaceutical company that made a liquid cherry flavored gastroprokinetic drug for adults, who received the lion’s share of the settlement?
        1. The patients/plaintiff
        2. The attorneys
        3. Others

        VIDEO

        Patient Safety: Gabapentin and Trazadone: Off-label Use is Out of Control-Recorded Webinar

        About this Course

        This course is a recorded (home study version) of the CE Finale Encore Webinars.

         

        Learning Objectives

        Upon completion of this knowledge based CE Activity, a pharmacist will be able to:

        ·        LIST the numerous off label uses of gabapentin and trazodone.
        ·        DESCRIBE which of those uses are supported by actual evidence
        ·        INDICATE the potential adverse effects and medication related problems that patients who take these drugs may experience
        ·        ARTICULATE ways to approach prescribers with alternative suggestions

        Release and Expiration Dates

        Released:  December 15, 2023
        Expires:  December 15, 2026

        Course Fee

        $17 Pharmacist

        ACPE UAN

        0009-0000-23-044-H05-P

        Session Code

        23RW44-WYX48

        Accreditation Hours

        1.0 hours of CE

        Additional Information

         

        How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

        Accreditation Statement

        The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

        Pharmacists and Pharmacy Technicians are eligible to participate in this knowledge-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-23-044-H05-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

        Grant Funding

        There is no grant funding for this activity.

        Faculty

        Jeannette Y. Wick, RPh, MBA, FASCP
        Director OPPD
        University of Connecticut School of Pharmacy
        Storrs, CT

        Faculty Disclosure

        In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

        • Jeannette  Wick has no relationships with ineligible companies

        Disclaimer

        The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

        CONTENT

        POST TEST

        Patient Safety: Gabapentin and Trazodone, Off-label Use is Out of Control
        LEARNING OBJECTIVES
        At the end of this continuing education activity, pharmacists will be able to
        1. LIST the numerous off label uses of gabapentin and trazodone
        2. DESCRIBE which of those uses are supported by actual evidence
        3. INDICATE the potential adverse effects and medication related problems that patients who take these drugs may experience
        4. ARTICULATE ways to approach prescribers with alternative suggestions

        1. Which of the following is an off-label use for gabapentin?
        A. Postherpetic neuralgia
        B. Adjunctive therapy in partial seizures
        C. Migraine prophylaxis

        2. Which of the following is an off-label use for trazodone?
        A. Chronic insomnia
        B. Major depressive disorder
        C. Pruritis

        3. Which of gabapentin’s off-label uses has the strongest evidence to support it?
        A. Bipolar disorder
        B. Alcohol withdrawal syndrome
        C. Pain syndromes

        4. Which of trazodone’s off-label uses has the strongest evidence to support it?
        A. Little evidence is available to support the use of trazodone in any of its purported off-label uses.
        B. The best evidence supports its use in chronic insomnia, with more than 15 RCTs indicating it is effective.
        C. A surprise finding has been that it is effective for behavioral issues in kids who have ADHD; it may help adults, too.

        5. Which if the following links gabapentin and trazodone to a most common adverse effect?
        A. Gabapentin = dose-dependent CNS and respiratory depression; trazodone = nausea/vomiting, xerostomia, dizziness, drowsiness
        B. Gabapentin = dose-dependent CNS priapism and suicidal ideation; trazodone = hypersensitivity reactions and peripheral edema
        C. Gabapentin = cardiac arrythmias and QT prolongation; trazodone = cumulative depressant effects when given with SSRIs

        Handouts

        VIDEO

        LAW: Off-Label Drug Use and The Pharmacists Role-RECORDED WEBINAR

        About this Course

        This course is a recorded (home study version) of the CE Finale Encore Webinars.

         

        Learning Objectives

        Upon completion of this application based CE Activity, a pharmacist will be able to:

        1. Define the term "off-label" in terms of drug promotion, prescribing, and use.
        2. Distinguish between the use of unapproved drugs and unapproved uses of approved drugs.
        3. List at least two reasons why off-label drug promotion could be harmful to patients.
        4. Explain whether a pharmacist has an obligation to dispense (or not dispense) a drug prescribed for an off label
        use.
        5. Identify potential liabilities for pharmacists who recommend off-label use of a drug.

        Release and Expiration Dates

        Released:  December 15, 2023
        Expires:  December 15, 2026

        Course Fee

        $17 Pharmacist

        ACPE UAN

        0009-0000-23-037-H03-P

        Session Code

        23RW37-ABC28

         

        Accreditation Hours

        1.0 hours of CE

        Additional Information

         

        How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

        Accreditation Statement

        The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

        Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-23-037-H03-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

        Grant Funding

        There is no grant funding for this activity.

        Faculty

        Jennifer A. Osowiecki, RPh, JD
        Cox & Osowiecki, LLC
        Suffield, Connecticut  

        Faculty Disclosure

        In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

        • Attorney Osowiecki has no relationships with ineligible companies

        Disclaimer

        The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

        Content

        Post Test (for viewing only)

        Post Test
        2023 CE Finale – LAW: Off-Label Drug Use and the Pharmacist’s Role

        1. Which of the following statements about off-label drug use is TRUE?
        a. Connecticut’s Pharmacy Practice Act prohibits a pharmacist from dispensing a drug for a use other than its FDA-approved indication.
        b. Drug companies have a First Amendment (“free speech”) right to promote FDA-approved drugs for unapproved indications.
        c. Pharmacists who have declined to fill a prescription for an unapproved use have been found liable for interfering with the prescriber-patient relationship.

        2. According to the FDA, which of the following statements about unapproved drugs and unapproved uses of approved drugs is FALSE?
        a. Unapproved drugs have not been cleared as safe and effective by the FDA.
        b. All drugs compounded pursuant to a prescription are unapproved drugs.
        c. The importation and use of an unapproved drug is prohibited in all circumstances.

        3. According to the Agency for Healthcare Research and Quality (AHRQ), off-label prescribing accounts for approximately what percentage of all prescriptions in the United States?
        a. 3%
        b. 20%
        c. 40%

        4. A patient asks the pharmacist to mix up some “Magic Mouthwash” consisting of two FDA-approved OTC medications (such as Benadryl liquid and Mylanta) to treat mouth sores. What should the pharmacist tell the patient?
        a. The pharmacist needs to do some research; if research indicates this product is effective, he can make it.
        b. A prescription is needed because the pharmacist is compounding two FDA-approved drugs for an unapproved use.
        c. The pharmacist can make Magic Mouthwash because both medications are OTC (not prescription-only).

        5. Which of the following statements about pharmacist responsibilities when dispensing FDA-approved drugs for an unapproved use is TRUE?
        a. Unless it’s a prescription for a compounded drug, a pharmacist is obligated to verify the intended use of each drug that is dispensed pursuant to a prescription.
        b. When a pharmacist recognizes that a prescription is for an off-label use, the pharmacist is obligated to inform the patient that the use is not approved by the FDA.
        c. If a pharmacist recommends an off-label use of a drug to a prescriber, the pharmacist should be aware of evidence-based support for the use.

        Handouts

        VIDEO

        The ABCD of Off-Label Medications for Weight Management-RECORDED WEBINAR

        About this Course

        This course is a recorded (home study version) of the CE Finale Encore Webinars.

         

        Learning Objectives

        Upon completion of this application based CE Activity, a pharmacist will be able to:

        1.     Discuss the main principles of management of adiposity-based chronic disease (ABCD)
        2.     Identify the efficacy of commonly prescribed medications that may be used off-label for weight reduction
        3.     List major safety considerations for medications prescribed off-label for weight reduction

        Release and Expiration Dates

        Released:  December 15, 2023
        Expires:  December 15, 2026

        Course Fee

        $17 Pharmacist

        ACPE UAN

        0009-0000-23-038-H01-P

        Session Code

        23RW38-CBA96

        Accreditation Hours

        1.0 hours of CE

        Additional Information

         

        How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

        Accreditation Statement

        The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

        Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-23-038-H01-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

        Grant Funding

        There is no grant funding for this activity.

        Faculty

        Khanh Dang, PharmD, CDCES, FNAP
        Clinical Professor
        UConn School of Pharmacy
        Storrs, CT

        Faculty Disclosure

        In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

        • Dr. Dang has no relationships with ineligible companies

        Disclaimer

        The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

        Content

        Post Test

        Post Test

        The ABCD of Off-Label Medications for Weight Management
        Post Test
        1. When working with a patient to manage ABCD, what is the first goal?

        A. prevent weight regain
        B. stop further weight gain
        C. achieve weight reduction

        2. Which of the following is the correct order of weight reduction efficacy (highest to lowest)?

        A. tirzepatide > semaglutide > phentermine
        B. semaglutide > SGLT2 inhibitors > phentermine
        C. metformin = semaglutide > topiramate

        3. What did the SELECT RCT report about patients 45 years and older with ABCD and existing cardiovascular disease who did not have diabetes?

        A. The placebo-subtracted weight reduction for weekly semaglutide 2.4 mg was 15% of baseline body weight.
        B. Subcutaneous semaglutide 2.4 mg once weekly reduced major adverse cardiovascular events in ABCD.
        C. Subcutaneous semaglutide 2.4 mg once weekly significantly reduced weight but did not prevent cardiovascular events.

        4. What is the most common adverse reaction for GLP-1 receptor agonist-based medications?

        A. nausea and other gastrointestinal adverse effects
        B. hypoglycemia
        C. sleep disturbance

        5. With which drug class can tirzepatide interact ?

        A. beta blockers
        B. ACE inhibitors
        C. oral hormonal contraceptives

        Handouts

        VIDEO

        TOP 10 Cardiovascular Drugs Used Off Label!!!-RECORDED WEBINAR

        About this Course

        This course is a recorded (home study version) of the CE Finale Encore Webinars.

         

        Learning Objectives

        Upon completion of this application based CE Activity, a pharmacist will be able to:

        • Identify how an FDA approved and off label indication differ and the implications of that differential designation
        • Identify which 10 FDA approved cardiovascular drugs have the most promising off label uses for treating other cardiac or noncardiac disorders
        • Describe the mechanisms of action for the purported off label uses of these drugs
        • Identify which national guidelines or consensus statements recommend the off-label use of drugs

        Release and Expiration Dates

        Released:  December 15, 2023
        Expires:  December 15, 2026

        Course Fee

        $17 Pharmacist

        ACPE UAN

        0009-0000-23-039-H01-P

        Session Code

        23RW39-TXJ88

        Accreditation Hours

        1.0 hours of CE

        Additional Information

         

        How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

        Accreditation Statement

        The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

        Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-23-039-H01-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

        Grant Funding

        There is no grant funding for this activity.

        Faculty

        C. Michael White, PharmD, FCCP, FCP
        BOT Distinguished Professor and Chair of Pharmacy Practice
        University of Connecticut School of Pharmacy
        Storrs, CT              

        Faculty Disclosure

        In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

        • Dr. White has no relationships with ineligible companies

        Disclaimer

        The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

        Content

        Post Test

        Post Test “TOP 10 Cardiovascular Drugs Used Off Label!!!”

        1. Which of the following drugs has been used to enhance the chances of delivering a baby in patients with Factor 5 Leiden and what is the mechanism of benefit?
        a) Thiazide diuretics; reduced placental calcium that stops crystalline umbilical cord blockage
        b) LMWH; preventing placental thrombosis in patients who are hypercoagulable
        c) Disopyramide – decreasing the inotropic effect in hypertrophic cardiomyopathy that leads to placental detachment

        2. Which of the following drugs is effective for treating anal fissures and what is the mechanism of action?
        a) IV iron; iron deficiency anemia promotes fissure formation so treating it reverses fissure
        b) Amiodarone; overactive potassium channels in the anus lead to apoptosis of anal mucosal cells
        c) CCBs; Blood vessel dilation enhancing blood flow to targeted areas in the body

        3. Which of the following drugs is properly linked to the off-label indication it is commonly used for?
        a) Beta-blockers – Raynaud’s phenomenon
        b) Prazosin – Nightmares in PTSD patients
        c) Clonidine – Stage fright

        4. Which of the following drugs is used off label for the treatment of abnormal face and body hair growth in patients and what is the mechanism of action?
        a) Spironolactone – blocking the effects of testosterone in several ways
        b) Beta-blockers – blocking epinephrine induced follicular stimulation
        c) Clonidine – central outflow of norepinephrine causes abnormal hair growth

        5. Sally Sue has had atrial fibrillation for several months. Her cardiologist has prescribed several therapies that have been ineffective, and one that is on the drug shortage list and hard to find. Which of the following might the cardiologist use off-label according to the AHA/ACC Guideline?

        a) Calcium channel blockers
        b) Prazocin
        c) Amiodarone

        Handouts

        VIDEO